<DOC>
	<DOCNO>NCT02583685</DOCNO>
	<brief_summary>This prospective , randomize study evaluate efficacy safety switch treatment Peg-interferon Ribavirin direct-acting antiviral agent Chinese CHC genotype 1b infection , interferon/ribavirin-intolerant .</brief_summary>
	<brief_title>Switching Regimen Treating Cirrhotic HCV GT1b Subjects</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Individuals chronic HCV GT1b infection ; HCV RNA ≥ 10000 IU/mL screening ; Received 4 week pegylated interferon plus ribavirin ( PR4 ) therapy intolerant PR4 ; Cirrhosis determination ; liver biopsy may require ; Use highly effective contraception method female childbearing potential sexually active male ; Pregnant nursing female male pregnant female partner ; HIV HBV coinfection ; Hematologic biochemical parameter Screening outside protocol specify requirement ; Active recent history ( ≤ 1 year ) drug alcohol abuse ; History current evidence condition , therapy , laboratory abnormality circumstance might confound result study , interfere subject 's participation full duration study , best interest subject participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>